Renovaro Inc (RENB)

Mar 3, 2025, 9:15 AM EST - 4 weeks ago

Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology

Feb 26, 2025, 1:25 PM EST - 5 weeks ago

Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

Feb 26, 2025, 9:15 AM EST - 5 weeks ago

Renovaro Announces $15 million in Equity Committed

Jan 7, 2025, 6:51 PM EST - 3 months ago

PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI

POAI

Jan 7, 2025, 9:15 AM EST - 3 months ago

Renovaro Appoints Nathen Fuentes as Chief Financial Officer

Jan 7, 2025, 9:15 AM EST - 3 months ago

Renovaro Issues Shareholder Letter and Provides Corporate Update

Jan 6, 2025, 9:15 AM EST - 3 months ago

Renovaro to Acquire Predictive Oncology in All-Stock Transaction

Dec 30, 2024, 9:00 AM EST - 3 months ago

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Dec 23, 2024, 9:00 AM EST - 3 months ago

RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program

Dec 20, 2024, 3:40 PM EST - 3 months ago

Renovaro Regains Compliance with NASDAQ Listing Requirement

Dec 20, 2024, 9:00 AM EST - 3 months ago

Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

Oct 17, 2024, 9:15 AM EDT - 6 months ago

RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing

Oct 16, 2024, 9:28 AM EDT - 6 months ago

Renovaro Announces Strategic Restructuring and Leadership Transition

Sep 13, 2024, 9:00 AM EDT - 7 months ago

RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress

Sep 11, 2024, 9:15 AM EDT - 7 months ago

RenovaroCube Announces Strategic Offering of Up to 20% Ownership

Jun 14, 2024, 9:06 AM EDT - 10 months ago

Renovaro, Inc. Announces $10 million in Equity Committed

May 24, 2024, 9:20 AM EDT - 11 months ago

Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy

May 21, 2024, 8:39 AM EDT - 11 months ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)

BAX RAPT SAGE TMCI

Apr 30, 2024, 11:00 AM EDT - 1 year ago

Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

Apr 24, 2024, 9:00 AM EDT - 1 year ago

RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership

Apr 18, 2024, 8:45 AM EDT - 1 year ago

Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient C

Feb 15, 2024, 9:25 AM EST - 1 year ago

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Feb 14, 2024, 10:01 AM EST - 1 year ago

Statement of Renovaro Inc

Feb 13, 2024, 9:31 AM EST - 1 year ago

AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine

Jan 25, 2024, 12:45 PM EST - 1 year ago

Renovaro Biosciences Announces Results of Special Meeting of Shareholders

Jan 16, 2024, 8:00 AM EST - 1 year ago

Message from Renovaro Bioscience, Inc.'s CEO, The Hon. Mark Dybul, MD

Jan 10, 2024, 5:21 PM EST - 1 year ago

RENOVARO BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Renovaro Biosciences Inc. - RENB

Oct 11, 2023, 9:25 AM EDT - 1 year ago

Avram Miller, Co-Founder of Intel Capital, Joins Renovaro Biosciences Board of Directors

Oct 10, 2023, 8:00 AM EDT - 1 year ago

Renovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors

Oct 2, 2023, 12:05 PM EDT - 1 year ago

Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD

Oct 2, 2023, 9:25 AM EDT - 1 year ago

AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine

Sep 29, 2023, 9:15 AM EDT - 1 year ago

Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine

Sep 29, 2023, 9:15 AM EDT - 1 year ago

GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine

Aug 30, 2023, 9:15 AM EDT - 1 year ago

Renovaro BioSciences Welcomes GEDiCube Announcement of New Joint Effort

Aug 21, 2023, 9:15 AM EDT - 1 year ago

Renovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical Officer

Aug 9, 2023, 9:00 AM EDT - 1 year ago

AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer

Jun 23, 2023, 5:00 PM EDT - 1 year ago

Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting

Jun 8, 2023, 8:45 AM EDT - 1 year ago

Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review

Apr 3, 2023, 9:00 AM EDT - 2 years ago

Enochian BioSciences' CEO Letter to Shareholders

Mar 29, 2023, 9:00 AM EDT - 2 years ago

Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher

Mar 13, 2023, 8:30 AM EDT - 2 years ago

Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements

Feb 23, 2023, 4:04 PM EST - 2 years ago

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022

Nov 30, 2022, 5:20 PM EST - 2 years ago

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022

Oct 24, 2022, 8:00 AM EDT - 2 years ago

Enochian BioSciences Forges Ahead With Focused Approach, Promising Future

Oct 21, 2022, 5:00 PM EDT - 2 years ago

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-K

Oct 17, 2022, 8:30 AM EDT - 2 years ago

Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology Platform

Sep 26, 2022, 8:21 AM EDT - 2 years ago

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Enochian Biosciences, Inc. with Losses of $100,000 to Contact the Firm

Sep 23, 2022, 8:08 AM EDT - 2 years ago

MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Enochian Biosciences, Inc. with Losses of $100,000 to Contact the Firm